SECONDARY MYELODYSPLASTIC SYNDROME
Clinical trials for SECONDARY MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new SECONDARY MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for SECONDARY MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New chemo cocktail aims to keep leukemia from coming back after transplant
Disease control OngoingThis study tests whether giving two chemotherapy drugs (clofarabine and melphalan) before a donor stem cell transplant can help prevent leukemia from returning in patients whose cancer is in remission. The approach aims to kill any remaining cancer cells and stop the immune syste…
Matched conditions: SECONDARY MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 10:05 UTC
-
New combo shows promise for Treatment-Linked blood cancer
Disease control OngoingThis study tests whether combining venetoclax and azacitidine can help people with a type of blood cancer called therapy-related myelodysplastic syndrome (t-MDS), which develops after prior cancer treatments. About 33 adults with intermediate to very high risk t-MDS will receive …
Matched conditions: SECONDARY MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: Uma Borate • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Experimental combo offers hope for tough blood cancers
Disease control OngoingThis early-stage study tests a combination of two drugs—ipilimumab, which boosts the immune system to attack cancer, and decitabine, a chemotherapy drug—in people whose myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) has returned or not responded to prior treatment…
Matched conditions: SECONDARY MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:03 UTC